Adding salmeterol to fluticasone did not increase serious asthma events and reduced exacerbations
Authors: Matthew B. Stanbrook
Journal: Annals of Internal Medicine (2016)

ACP Journal Club15 November 2016Adding salmeterol to fluticasone did not increase serious asthma events and reduced exacerbationsMatthew B. Stanbrook, MD, PhDMatthew B. Stanbrook, MD, PhDToronto Western Hospital, University of Toronto, Toronto, Ontario, Canada (M.B.S.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/ACPJC-2016-165-10-057 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationStempel DA, Raphiou IH, Kral KM, et al; AUSTRI Investigators. Serious asthma events with fluticasone plus salmeterol versus fluticasone alone. N Engl J Med. 2016;374:1822-30. https://pubmed.ncbi.nlm.nih.gov/26949137Clinical Impact RatingsGIM/FP/GP: Allerg & Immunol: Pulmonology: References1 Nelson HS, Weiss ST, Bleecker ER, et al; SMART Study Group. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest. 2006;129:15-26. [PMID: 16424409] Google Scholar2 Castle W, Fuller R, Hall J, Palmer J. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ. 1993;306:1034-7. [PMID: 8098238] Google Scholar3 Global Initiative for Asthma (GINA). 2016 GINA report: global strategy for asthma management and prevention. http://ginasthma.org/2016-gina-report-global-strategy-for-asthma-management-and-prevention/ (accessed 12 Oct 2016). Google Scholar4 Chowdhury BA, Seymour SM, Levenson MS. Assessing the safety of adding LABAs to inhaled corticosteroids for treating asthma. N Engl J Med. 2011;364:2473-5. [PMID: 21714647] Google Scholar5 Ducharme FM, Ni Chroinin M, Greenstone I, Lasserson TJ. Addition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma. Cochrane Database Syst Rev. 2010;(4):CD005533. [PMID: 20393943] Google Scholar6 Wechsler ME, Kunselman SJ, Chinchilli VM, et al; National Heart, Lung and Blood Institute's Asthma Clinical Research Network. Effect of beta2-adrenergic receptor polymorphism on response to longacting beta2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial. Lancet. 2009;374:1754-64. [PMID: 19932356] Google Scholar Author, Article, and Disclosure InformationAffiliations: Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada (M.B.S.)This article was published at Annals.org on 1 November 2016. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 15 November 2016Volume 165, Issue 10Page: JC57KeywordsAdolescentsAsthmaChildrenEmergency departmentFood and Drug AdministrationHazard ratioHospitalizationsIntubationReproducibilitySafety ePublished: 15 November 2016 Issue Published: 15 November 2016 Copyright & PermissionsCopyright © 2016 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...